metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Variabilidad genética del virus de la hepatitis C en el área de salud de Elche...
Journal Information
Vol. 26. Issue 7.
Pages 407-410 (January 2003)
Share
Share
Download PDF
More article options
Vol. 26. Issue 7.
Pages 407-410 (January 2003)
Full text access
Variabilidad genética del virus de la hepatitis C en el área de salud de Elche. Correlación entre el antígeno del core y la carga viral
Genetic Variability Of The Hepatitis C Virus In The Health Area Of Elche (Spain). Correlation Between The Core Antigen And Viral Load
Visits
4612
J.C. Rodrígueza,
Corresponding author
micro_elx@gva.es

Correspondencia: Dr. J.C. Rodríguez. Servicio de Microbiología. Hospital General Universitario de Elche. Huertos y Molinos, s/n. 03203 Elche. Alicante. España.
, J. Garcíaa, I. Moyaa, A. Ayeloa, N. Vázquezb, C. Sillerob, G. Royoa
a Servicio de Microbiología. Hospital General Universitario de Elche. Universidad Miguel Hernández. Elche. Alicante. España
b Servicio del Aparato Digestivo. Hospital General Universitario de Elche. Universidad Miguel Hernández. Elche. Alicante. España
This item has received
Article information
Resumen

Se ha investigado la prevalencia de los diferentes genotipos del virus de la hepatitis C (VHC) en el Área de Salud de Elche sobre un total de 281 pacientes estudiados entre marzo de 2000 y marzo de 2002. De ellos, 55 estaban coinfectados con el virus de la inmunodeficiencia humana (VIH).

Abstract

Se ha relacionado el genotipo con la carga viral y la coexistencia de infección por el VIH. Asimismo, se ha establecido la relación de estos parámetros con la presencia del antígeno del core del VHC.

Los resultados permiten establecer que el genotipo 1b es el que presenta mayor prevalencia (38,4%), seguido del genotipo 3a (23,1%). Los pacientes coinfectados por el VIH presentan menos infecciones debidas a genotipos del grupo 1 (p < 0,05).

Los pacientes infectados por el VIH presentan una mayor carga viral en todos los genotipos, sobre todo el genotipo 3. La detección del antígeno del core del VHC presenta una buena correlación con la determinación de la carga viral. Aunque todavía no ha sido suficientemente evaluada, la determinación del antígeno del core del VHC constituye una técnica sencilla que puede contribuir, en el futuro, a mejorar el manejo de los pacientes con hepatitis crónica por el VHC.

Abstract

We investigated the prevalence of the various genotypes of hepatitis C virus (HCV) in 281 patients evaluated between March, 2000 and March, 2002 in the health area of Elche. Of these patients, 55 were coinfected with human immunodeficiency virus (HIV).

The genotype was related to viral load and the co-existence of HIV infection. Likewise, the relationship between these parameters and the presence of the HCV core antigen was established.

The results indicate that genotype 1b was the most prevalent (38.4%) followed by genotype 3a (23.1%). Patients coinfected with HIV presented fewer infections due to group 1 genotypes (p < 0.05).

Patients with HIV presented a greater viral load in all the genotypes, with genotype 3 presenting a high viral load. Detection of the HCV core antigen showed a close correlation with viral load determinations. Although not yet sufficiently assessed, determination of the HCV core antigen constitutes a simple technique that could eventually contribute to improving the management of patients with chronic HCV hepatitis.

Full text is only aviable in PDF
Bibliografía
[1.]
M.P. Cooreman.
Schoondermark Van de Ven E.M. Hepatitis C virus: biological and clinical consequences of genetic heterogenicity.
Scand J Gastroenterol, 218 (1996), pp. 106-115
[2.]
A. Sánchez-Quijano, M.A. Abad, R. Torronteras, C. Rey, J.A. Pineda, M. Leal, et al.
Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain.
J Hepatol, 27 (1997), pp. 25-29
[3.]
T.A. Cha, B. Beall, J. Irvine, J. Kolberg, D. Chien, G. Kuo, et al.
At least five related, but distinct, hepatitis C viral genotypes exist.
Proc Natl Acad Sci USA, 89 (1992), pp. 7144-7148
[4.]
P. León, J.A. López, C. Amela, C. Elola, JM. Echevarría.
Prevalencia de tipos del virus de la hepatitis C en donantes de sangre españoles: resultados de un estudio multicéntrico de ámbito estatal. Grupo Español de Estudio de Donantes de Sangre en Riesgo de Transmisión del VHC. (GEDSRT-VHC).
Enferm Infecc Microbiol Clin, 17 (1999), pp. 448-453
[5.]
F.X. López Labrador, S. Ampurdanes, X. Forns, A. Castells, J.C. Sáiz, J. Costa, et al.
Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis ad hepatocellular carcinoma. J.
Hepatol, 27 (1997), pp. 959-965
[6.]
M.H. Elghouzzi, F. Bouchardeau, J. Pillonel, E. Boiret, C. Tirtaine, V. Barlet, et al.
Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors.
Vox Sang, 79 (2000), pp. 138-144
[7.]
J.M. Pawlotsky, L. Taskiris, F. Roudot-Thoraval, C. Pellet, L. Stuyver, J. Duval, et al.
Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.
C J Infect Dis, 171 (1995), pp. 1607-1610
[8.]
T. Pérez-Gracia, F. Galán, C. Fernández-Gutiérrez, J.A. Girón, M. Rodríguez-Iglesias.
Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes.
Liver, 19 (1999), pp. 288-293
[9.]
M. Rubio, C. Rubio, A. Nogués, A. Manonelles.
Genotipos del virus de la hepatitis C. Estudio de 302 pacientes coinfectados por el virus de la inmunodeficiencia humana.
Med Clin (Barc), 116 (2001), pp. 650-651
[10.]
R. Bravo, V. Soriano, J. García-Samaniego, J. González, A. Castro, M. Colmenero, et al.
Prevalencia de los genotipos del virus de la hepatitis C en drogadictos españoles con hepatitis crónica C. Grupo Español para el Estudio de las Hepatitis víricas en Pacientes VIH +.
Rev Clin Esp, 196 (1996), pp. 673-677
[11.]
L.M. Blatt, M.G. Mutchnick, M.J. Tong, F.M. Klion, E. Lebovics, B. Freilich, et al.
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States.
J Viral Hepat, 7 (2000), pp. 196-202
[12.]
D.B. Smith, F. Davidson, P. Yap, H. Brown, J. Kolberg, J. Detmer, et al.
Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group.
J Infect Dis, 173 (1996), pp. 727-730
[13.]
J.Y. Lau, G.L. Davis, L.E. Prescott, G. Maertens, K.L. Lindsay, K. Qian, et al.
Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group.
Ann Intern Med, 124 (1996), pp. 868-876
[14.]
M. Bonacini, S. Govindarajan, L.M. Blatt, P. Schmid, A. Conrad, K.L. Lindsay, et al.
Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.
J Viral Hepat, 6 (1999), pp. 203-208
[15.]
J.J. Goedert, A. Hatzakis, K.E. Sherman, M.E. Eyster.
Lack of association of hepatitis C virus load and genotype with risk of endstage liver disease in patients with human immunodeficiency virus coinfection.
J Infect Dis, 184 (2001), pp. 1202-1205
[16.]
D. Neau, P. Trimoulet, M. Winnock, B. Le-Bail, E. Schvoerer, E. Legrand, et al.
Impact of protease inhibitors on intrahepatic hepatitis C virus viral load.
AIDS, 15 (2001), pp. 1736-1738
[17.]
D. Torre, R. Tambini, F. Cadario, C. Barbarini, M. Moroni, C. Basilico.
Evolution of coinfection with human immunodeficiency virus and hepatitis C virus patients treated with highly antiretroviral therapy.
Clin Infect Dis, 33 (2001), pp. 1579-1585
[18.]
K. Aoyagi, C. Ohue, K. Iida, T. Kimura, E. Tanaka, K. Kiyosawa, et al.
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.
J Clin Microbiol, 37 (1999), pp. 1802-1808
[19.]
G. Icardi, F. Ansaldi, B.M. Bruzzone, P. Durando, S. Lee, C. De Luigi, et al.
Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen.
J Clin Microbiol, 39 (2001), pp. 3110-3114
[20.]
J.B. Kurtz, E. Boxall, N. Qusir, J. Shirley, D. Coleman, C. Chandler.
The diagnostic significance of an assay for total hepatitis C core antigen.
J Virol Methods, 96 (2001), pp. 127-132
[21.]
E. Tanaka, C. Ohue, K. Aoyagi, K. Yamaguchi, S. Yagi, K. Kiyosawa, et al.
Evaluation of a new enzyme immunoassay for Hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.
Hepatology, 32 (2000), pp. 388-393
[22.]
L.M. Lagging, C.E. García, J. Westin, R. Wejstal, G. Norkrans, A.P. Dhillon, et al.
Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time.
J Clin Microbiol, 40 (2002), pp. 4224-4229
[23.]
M. Bouvier-Alias, K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, et al.
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
Hepatology, 36 (2002), pp. 211-218
[24.]
J. Mellor, A. Hawkins, P. Simmonds.
Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.
J Clin Microbiol, 37 (1999), pp. 2525-2532
[25.]
J.M. Pawlotsky.
Use and interpretation of virological tests for hepatitis C.
Hepatology, 36 (2002), pp. S65-73
[26.]
Lunel F, Veillon P, Payan C. Hepatitis C virus RNA and HCV core antigen kinetics predict the efficiency of alfa-interferon and ribavirin therapy in naive patients infected by hepatitis c virus genotype 2 or 3 [abstract V-235]. 42nd ICAAC Abstract. American Society for Microbiology, September 27-30, San Diego, p. 426.
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos